Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00

Arcus Biosciences (NYSE:RCUS) had its target price boosted by Truist Financial from $40.00 to $41.00 in a report published on Wednesday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

A number of other equities analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a report on Friday, September 11th. TD Cowen initiated coverage on shares of Arcus Biosciences in a report on Wednesday, September 16th. They set a “buy” rating for the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Arcus Biosciences in a research report on Friday, August 7th. Finally, Wedbush upped their price objective on shares of Arcus Biosciences from $43.00 to $49.00 and gave the company an “outperform” rating in a research note on Wednesday. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.64.

Arcus Biosciences Stock Down 4.2%

Shares of Arcus Biosciences stock opened at $18.54 on Wednesday. The stock has a 50-day moving average price of $26.12 and a 200 day moving average price of $26.14. The company has a market cap of $2.36 billion, a P/E ratio of -4.75 and a beta of 0.94. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 0.22. Arcus Biosciences has a 1 year low of $16.87 and a 1 year high of $31.74.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.17. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The firm had revenue of $41.00 million during the quarter, compared to analyst estimates of $21.98 million. The firm’s revenue was down 74.4% compared to the same quarter last year. As a group, analysts expect that Arcus Biosciences will post -3.55 EPS for the current fiscal year.

Insider Activity at Arcus Biosciences

In related news, CAO Alexander Azoy sold 2,827 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently made changes to their positions in RCUS. Integrated Wealth Concepts LLC acquired a new position in shares of Arcus Biosciences during the 2nd quarter worth about $30,000. KBC Group NV acquired a new stake in Arcus Biosciences in the 1st quarter valued at approximately $50,000. Sterling Capital Management LLC grew its holdings in Arcus Biosciences by 328.4% in the 3rd quarter. Sterling Capital Management LLC now owns 2,716 shares of the company’s stock valued at $70,000 after buying an additional 2,082 shares during the last quarter. Royal Bank of Canada grew its holdings in Arcus Biosciences by 14.6% in the 1st quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after buying an additional 607 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Arcus Biosciences by 10.0% in the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after buying an additional 359 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analyst support: Truist Financial and Wedbush both forecast strong price appreciation for RCUS, suggesting analysts see upside following the recent selloff. Truist Financial Forecasts Strong Price Appreciation for Arcus Biosciences Wedbush Forecasts Strong Price Appreciation for Arcus Biosciences
• Positive Sentiment: Promising casdatifan data: Arcus presented new ARC-20 data evaluating casdatifan across multiple lines of therapy in kidney cancer. The results may support the drug’s development and commercial potential, though investors are likely seeking additional details on efficacy and durability. Arcus Presents New Casdatifan Data
• Neutral Sentiment: Improved liquidity: Arcus estimates it held approximately $694 million in cash, cash equivalents and marketable securities as of September 30, 2026. Proceeds from the offering should further extend its funding runway for clinical development, but the benefit comes with shareholder dilution. Arcus Estimates Cash Position
• Negative Sentiment: Equity dilution: Arcus priced an underwritten public offering of 14.29 million shares at $17.50 per share, expected to raise $250 million before expenses. The discounted issuance increases the share count and was the primary catalyst for the stock’s decline. Arcus Prices $250 Million Offering
• Negative Sentiment: Investor litigation risk: Kuehn Law said it is investigating potential fiduciary-duty violations and alleged self-dealing by company officers and directors. The announcement does not establish wrongdoing, but it adds reputational and legal uncertainty. Kuehn Law Investigation

Arcus Biosciences Company Profile

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.